PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
Clinical trial NCT06792162 · RECRUITING
Trial details
- NCT number
- NCT06792162
- Sponsor
- Peking University Third Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-20
- Primary completion
- 2026-04-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.